SCHEMBL376416

SCHEMBL376416

NC(=NS(=O)(=O)c1ccc(F)c([N+](=O)[O-])c1)c1ccc(N2CCC(=Cc3ccc(F)cc3)CC2)cc1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BCL2L1 Q07817 8/20 0.45
BCL2 P10415 4/20 0.45
MAPT P10636 6/20 0.40
LMNA P02545 4/20 0.40
ALDH1A1 P00352 6/20 0.39
CA1 P00915 2/20 0.39
CA2 P00918 2/20 0.39
CA9 Q16790 2/20 0.39
CA7 P43166 1/20 0.39
MITF O75030 1/20 0.37
GAA P10253 1/20 0.37
HTT P42858 1/20 0.37
NPSR1 Q6W5P4 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
THRA P10827 1/20 0.36
VDR P11473 1/20 0.36
CA12 O43570 1/20 0.36
VCAM1 P19320 1/20 0.36
CASP3 P42574 1/20 0.36
USP14 P54578 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13503904 1.00 BCL2L1 (0.45) BCL2L1BCL2MAPTLMNAALDH1A1
SCHEMBL376537 0.88 BCL2L1 (0.37) BCL2L1BCL2MAPTLMNAALDH1A1
SCHEMBL13503538 0.88 BCL2L1 (0.37) BCL2L1BCL2MAPTLMNAALDH1A1
SCHEMBL376987 0.84 BCL2L1 (0.48) BCL2L1BCL2MAPTLMNAALDH1A1
SCHEMBL13503559 0.84 BCL2L1 (0.48) BCL2L1BCL2MAPTLMNAALDH1A1
SCHEMBL377004 0.84 BCL2L1 (0.48) BCL2L1BCL2MAPTLMNAALDH1A1
SCHEMBL377005 0.84 BCL2L1 (0.48) BCL2L1BCL2MAPTLMNAALDH1A1
SCHEMBL13503523 0.84 BCL2L1 (0.48) BCL2L1BCL2MAPTLMNAALDH1A1
SCHEMBL376415 0.83 BCL2L1 (0.52) BCL2L1BCL2MAPTLMNAALDH1A1
SCHEMBL13503899 0.80 BCL2 (0.44) BCL2L1BCL2MAPTLMNAALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1765778-B1 N-SULFONYLCARBOXIMIDAMIDE APOPTOSIS PROMOTERS ABBOTT LAB (US) 2012-01-25 EP disclosed
US-20100035879-A1 N-SULFONYLCARBOXIMIDAMIDE APOPTOSIS PROMOTERS ABBOTT LABORATORIES 2010-02-11 US disclosed
US-7585858-B2 N-sulfonylcarboximidamide apoptosis promoters ABBOTT LABORATORIES (US) 2009-09-08 US disclosed
US-20050272744-A1 N-sulfonylcarboximidamide apoptosis promoters ABBVIE INC. 2005-12-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100035879-A1 N-SULFONYLCARBOXIMIDAMIDE APOPTOSIS PROMOTERS BAX, BCL2, BAD BCL2L1 18/4885BCL2 2/4885MAPT 4433/4885
US-20050272744-A1 N-sulfonylcarboximidamide apoptosis promoters BAX, BCL2, BAD BCL2L1 18/4885BCL2 2/4885MAPT 4433/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.